BridgeBio Pharma, Inc.
BBIO
株式のランク
#1613
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
株価
$68.06
最終同期: 2026-10-19
時価総額
$13.31B
変化（1日）
2.52%
変化（1年）
20.97%
国
US
取引 BridgeBio Pharma, Inc. (BBIO)
カテゴリー
Healthcare
BridgeBio Pharma, Inc.（BBIO）の発行済株式数
June 2026 時点の発行済株式数 195.79M
BridgeBio Pharma, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 195.79M です。December 2023 の終わりには、同社は 162.79M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
BridgeBio Pharma, Inc.（BBIO）の発行済株式数の履歴（2017 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 195.79M | 5.22% |
| 2024 | 186.08M | 14.30% |
| 2023 | 162.79M | 10.39% |
| 2022 | 147.47M | 2.16% |
| 2021 | 144.36M | 22.34% |
| 2020 | 118.00M | 12.27% |
| 2019 | 105.10M | 13.83% |
| 2018 | 92.33M | 0.00% |
| 2017 | 92.33M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 29.68% |
US
|
|
| 396.00M | 102.26% |
US
|
|
| 478.91M | 144.61% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -68.24% |
NL
|
